Who are the top shareholders of Foresight Group Holdings?

Foresight Group Holdings' top shareholders include the company's Top Key Executive Bernard Fairman (29% stake), Slater Investments Limited (5.4%), and Liontrust Asset Management PLC (5.2%). The CEO, Gary Fraser, also owns 4% of the shares.

Why is Foresight Group Holdings' ownership structure significant?

Institutions hold a majority 51% stake in Foresight Group Holdings, indicating strong interest and confidence from professional investors in the company's potential.

Home / Business and Economy / Institutional Investors Control 51% of Foresight Group Holdings

Institutional Investors Control 51% of Foresight Group Holdings

Q: What is Foresight Group Holdings working on?

Foresight Group Holdings is one of 20 companies under $10 billion in market capitalization that are leveraging AI technology to drive innovation in healthcare, from early diagnostics to drug discovery.

25 Aug

•

Summary

Institutions hold majority 51% stake in Foresight Group Holdings
Top 3 shareholders are a key executive, Slater Investments, and Liontrust Asset Management
Foresight Group Holdings is working on AI-powered healthcare innovations

Institutional Investors Control 51% of Foresight Group Holdings

According to the latest analysis as of August 25, 2025, institutional investors hold a majority 51% stake in Foresight Group Holdings, a company that is at the forefront of AI-powered healthcare innovations. This suggests that these professional investors see significant potential in Foresight's work, which spans early diagnostics to drug discovery.

The largest shareholder is Foresight's Top Key Executive, Bernard Fairman, who owns 29% of the company's shares. The second and third largest shareholders are Slater Investments Limited and Liontrust Asset Management PLC, holding 5.4% and 5.2% respectively. Additionally, the company's CEO, Gary Fraser, owns 4% of the shares.

Foresight Group Holdings is one of 20 promising healthcare companies under $10 billion in market capitalization that are leveraging AI technology to drive innovation. As institutional investors continue to show strong interest in the company, it suggests there may still be time for individual investors to get in on the ground floor of this potentially transformative healthcare technology.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.